Grants Search Results

This institution is a member of a research consortium which is being funded by St. Baldrick's: Pediatric Blood & Marrow Transplant Consortium. For a description of this project, see the consortium grant made to the lead institution: the National Marrow Donor Program, Minneapolis, MN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Pediatric Blood & Marrow Transplant Consortium. For a description of this project, see the consortium grant made to the lead institution: the National Marrow Donor Program, Minneapolis, MN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Pediatric Blood & Marrow Transplant Consortium. For a description of this project, see the consortium grant made to the lead institution: the National Marrow Donor Program, Minneapolis, MN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Pediatric Blood & Marrow Transplant Consortium. For a description of this project, see the consortium grant made to the lead institution: the National Marrow Donor Program, Minneapolis, MN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Pediatric Blood & Marrow Transplant Consortium. For a description of this project, see the consortium grant made to the lead institution: the National Marrow Donor Program, Minneapolis, MN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Pediatric Blood & Marrow Transplant Consortium. For a description of this project, see the consortium grant made to the lead institution: the National Marrow Donor Program, Minneapolis, MN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Pediatric Blood & Marrow Transplant Consortium. For a description of this project, see the consortium grant made to the lead institution: the National Marrow Donor Program, Minneapolis, MN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Pediatric Blood & Marrow Transplant Consortium. For a description of this project, see the consortium grant made to the lead institution: the National Marrow Donor Program, Minneapolis, MN.

Dr. Sondel has been using an immune-based therapy to treat children with cancer, and is seeing that it is clearly helping some patients. He recently found the presence of an antibody seems to predict which patients will do best with this treatment. This research aims to understand what this antibody is recognizing, and then to determine how it is helping the treatment to work better.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Pediatric Blood & Marrow Transplant Consortium. For a description of this project, see the consortium grant made to the lead institution: the National Marrow Donor Program, Minneapolis, MN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Pediatric Blood & Marrow Transplant Consortium. For a description of this project, see the consortium grant made to the lead institution: the National Marrow Donor Program, Minneapolis, MN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Pediatric Blood & Marrow Transplant Consortium. For a description of this project, see the consortium grant made to the lead institution: the National Marrow Donor Program, Minneapolis, MN.

Juvenile myelomonocytic leukemia (JMML) is a fatal childhood myeloid malignancy with limited therapeutic options. Relapse remains the main cause of treatment failure, most likely due to the persistence of leukemic stem cells, a small population of self-renewing precursor cells that are responsible for long-term maintenance of leukemia growth and drug resistance. This research tests for the therapeutic effects of Stat5 inhibition by pimozide, a clinically used antipsychotic drug, in a subtype of JMML caused by mutations in Ptpn11.

The immune system not only fights infection, but can also fight cancer cells. Recently, doctors have been able to use patients' own immune cells to help treat their cancer. Sometimes, cancer cells can hide from the immune cells. Dr. Richman, the Ben's Green Drakkoman St. Baldrick’s Fellow, aims to learn how cancer cells hide from immune cells, and how to make these cancer-killing immune cells more specific to tumor cells to avoid harming the patient's normal tissues.

This grant is named for the Ben's Green Drakkoman Fund, created to honor the memory of Ben Stowell who battled osteosarcoma with an inspiring determination to live life fully. The fund is named after a super hero Ben created named the Green Drakkoman who defeats his enemy, the Evil Alien.

Burkitt lymphoma is an aggressive cancer that occurs in children. Treatment requires intensive chemotherapy, which can have significant side effects. Targeted therapies, which kill cancer cells but spare healthy cells, are urgently needed. As the Jack’s Pack – We Still Have His Back St. Baldrick’s Scholar, Dr. Roth is investigating a promising new drug that kills Burkitt lymphoma by attacking a protein that the tumor needs to survive. This drug may treat Burkitt lymphoma with less side effects than chemotherapy.

This grant is named in memory of Jack Klein who bravely battled Burkitts Lymphoma. Love for this special boy inspired family and friends to rally around him as “Jack’s Pack” with their cry, “We Got Jack’s Back”.

Acute Myeloid Leukemia is an aggressive form of childhood cancer for which the therapy causes many side effects and the survival is 60%. Dr. Sakamoto's lab has found that a protein known as CREB is overproduced in AML cells and is associated with a worse prognosis. This research aims to study the protein RSK, which increases CREB activity in AML cells, and find ways to block RSK as a new approach to treat AML.

Based on progress to date, Dr. Shah was awarded a new grant in 2017 to fund an additional year of this Fellow award. One challenge in caring for solid tumor patients is monitoring treatment response, as doctors currently use radiology studies that are unable to detect residual disease. Circulating tumor DNA is released by cancer cells into the patient’s bloodstream and carries tumor-specific mutations. Circulating tumor DNA could be used as a marker to measure tumor burden by a simple blood draw. Researchers recently developed a tool to measure circulating tumor DNA in lung cancer patients. Dr. Shah aims to design a similar tool for three common pediatric tumors.

This additional grant is made with generous support from the Dorian J. Murray Foundation which was created in honor and in memory of Dorian 'Dstrong' Murray who passed away from Alveolar Rhabdomyosarcoma. The Foundation is committed to provide financial support to families of children fighting cancer, raise awareness and educate people and fund new and breakthrough research.

A portion of Dr. Shah's fellow award was named for the Sweet Caroline Fund, a Hero Fund created to honor the memory of Caroline Richards who was diagnosed with osteosarcoma. This fund pays tribute to her giving spirit and her compassion for others by supporting osteosarcoma research to help kids with cancer.

Ewing sarcoma is the second most common bone tumor in children and adolescents, and overall survival is dismal for patients with recurrent disease. Dr. Shelat recently identified an "Achilles’ heel" in this cancer, and showed that exploiting this weakness using a three drug cocktail cured the disease more than 80% of the time in models. This project is to validate this weakness as a marker for sensitivity to the drug cocktail in Ewing sarcoma and other pediatric cancers, and to find new drug combinations that better target this weakness.

Based on progress to date, Dr. Lian was awarded new grants in 2018 and 2019 to fund additional years of this International Scholar grant. Based on progress to date, Dr. Lian was awarded a new grant in 2018 to fund an additional year of this International Scholar grant. MYCN-driven neuroblastoma accounts for about 30% of neuroblastomas and is associated with an extremely poor prognosis. Casein Kinase 2 (CK2) is an enzyme that is currently in clinical trials to treat multiple cancers. However, its efficacy on MYCN-driven neuroblastoma remains unknown. Dr. Lian's research aims to test if CK2 inhibition can serve as a new strategy to treat MYCN-driven neuroblastoma. A portion of this grant was named for The Amanda Rozman Pediatric Cancer Research Fund, a St. Baldrick's Hero Fund created in memory of Amanda Rozman and honors her courageous battle with neuroblastoma by funding promising new treatments and clinical trials in the area of translational research.

Based on progress to date, Dr. Wasswa was awarded a new grant in 2018 to fund an additional year of this International Scholar grant. Whereas more than 80% of children with leukemia and lymphoma in the United States are cured with chemotherapy, in Africa a diagnosis with one of these diseases is an outright death sentence. To enable adaptation of chemotherapy protocols from the U.S. to treating children in Africa, Dr. Wasswa is studying the prevalent types of leukemia and lymphoma in children in Malawi and how their genetic code may affect response to chemotherapy.